Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Hoffmann, Peter [VerfasserIn]   i
 Globig, Anna-Maria [VerfasserIn]   i
 Thomann, Anne K. [VerfasserIn]   i
 Grigorian, Maximilian [VerfasserIn]   i
 Krisam, Johannes [VerfasserIn]   i
 Hasselblatt, Peter [VerfasserIn]   i
 Reindl, Wolfgang [VerfasserIn]   i
 Gauss, Annika [VerfasserIn]   i
Titel:Tofacitinib in treatment-refractory moderate to severe ulcerative colitis
Titelzusatz:real-world experience from a retrospective multicenter observational study
Verf.angabe:Peter Hoffmann, Anna-Maria Globig, Anne K. Thomann, Maximilian Grigorian, Johannes Krisam, Peter Hasselblatt, Wolfgang Reindl and Annika Gauss
E-Jahr:2020
Jahr:10 July 2020
Umfang:13 S.
Fussnoten:Gesehen am 22.09.2020
Titel Quelle:Enthalten in: Journal of Clinical Medicine
Ort Quelle:Basel : MDPI, 2012
Jahr Quelle:2020
Band/Heft Quelle:9(2020,7) Artikel-Nummer 2177, 13 Seiten
ISSN Quelle:2077-0383
Abstract:(1) Background: Tofacitinib is approved in Europe for the treatment of adults with moderately to severely active ulcerative colitis since 2018. Real-world efficacy and safety data are currently scarce. (2) Methods: We performed a retrospective multicenter study at three German tertiary outpatient clinics for inflammatory bowel diseases and included all patients who started tofacitinib therapy between August 2018 and March 2020. The primary endpoint was a combined endpoint of steroid-free clinical remission, steroid-free clinical response, or clinical response at week 8. Secondary endpoints were biochemical response at week 8, as well as steroid-free clinical remission, steroid-free clinical response or clinical response at week 24, respectively, adverse events by week 24, and need for colectomy by the end of follow-up. (3) Results: Thirty-eight patients with moderate-to-severe ulcerative colitis were included. Eleven patients (28.9%) achieved steroid-free clinical remission at week 8. Fifty-three percent of the patients were primary non-responders at week 8. Three severe adverse events (pneumonia, hospitalization for aggravation of ulcerative colitis, emergency colectomy due to colon perforation), and 12 adverse events were documented by week 8 of therapy. By the end of follow-up, seven patients (18.4%) had undergone colectomy.
DOI:doi:10.3390/jcm9072177
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.3390/jcm9072177
 DOI: https://doi.org/10.3390/jcm9072177
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:inflammatory bowel disease
 JAK inhibitor
 real-world
 small molecule
 tofacitinib
 ulcerative colitis
K10plus-PPN:1733547746
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68639422   QR-Code
zum Seitenanfang